PIPELINE EMBOLIZATION STENT FOR TREATMENT OF GIANT SUPRACLINOID ANEURYSMS: A CASE SERIES
Recommended Citation
Fana M, Alsrouji O, Rehman M. PIPELINE EMBOLIZATION STENT FOR TREATMENT OF GIANT SUPRACLINOID ANEURYSMS: A CASE SERIES. J NeuroIntervent Surg 2022; 14:A178-A179.
Document Type
Conference Proceeding
Publication Date
7-23-2022
Publication Title
J NeuroIntervent Surg
Abstract
Background Cerebrovascular aneurysms of the supraclinoid region are a technical challenge and can particularly difficult to treat when greater than 25mm in diameter. Such giant aneurysms can be approached with various skull-based and endovascular surgical techniques and the advent of the Pipeline embolization stent presents a new treatment modality. Previously used for treatment of small aneurysms, the Pipeline is a flow diverter device that is more recently being investigated in its use for treatment of giant aneurysms with few studies to date published on its procedural outcomes. Methods Here, we highlight the case of 3 patients presenting symptomatically to Henry Ford Hospital with giant supraclinoid aneurysms treated with the Pipeline stent and monitored on follow-up visits. We further review the most current case reports and the two clinical trials to-date investigating the utility of the Pipeline stent in treatment of large and giant cerebral aneurysms, highlighting the emerging evidence of its efficacy and long-term patient outcomes. Results We report successful resolution of presenting symptoms and radiographic evidence of aneurysm size reduction on all patient follow-ups after placement of a single Pipeline stent in each case (Figure 1). We further report one incidence of an intra-operative embolic stroke complication with near-complete recovery on close follow-up and no post-operative complication in all cases (Table 1). Conclusion The Pipeline embolization device is a novel technique that can be utilized for treatment of giant cerebrovascular aneurysms with emerging evidence of immediate and longterm success. Further patient enrollment and clinical trials will be required to assess its efficacy in comparison to other endovascular and surgical approaches for the treatment of giant aneurysms.
Volume
14
First Page
A178
Last Page
A179
